NCT03895099 New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Status COMPLETED Phase PHASE3
NCT03894124 Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers Status COMPLETED Phase PHASE1
NCT03893448 Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) Status COMPLETED Phase PHASE3
NCT03887442 Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy Status TERMINATED Phase PHASE2
NCT03885934 Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) Status COMPLETED Phase PHASE3
NCT03884101 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) Status COMPLETED Phase PHASE3
NCT03882801 Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039) Status COMPLETED Phase PHASE1
NCT03881111 First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study Status WITHDRAWN Phase PHASE3
NCT03880539 Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection Status COMPLETED Phase PHASE4
NCT03875092 A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study Status COMPLETED Phase PHASE3
NCT03873883 First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer Status COMPLETED Phase PHASE1
NCT03873038 Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004) Status COMPLETED Phase PHASE1
NCT03873025 A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Status WITHDRAWN Phase PHASE1/PHASE2
NCT03871959 Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma Status COMPLETED Phase PHASE1
NCT03867084 Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) Status COMPLETED Phase PHASE3
NCT03859739 Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002) Status COMPLETED Phase PHASE1
NCT03858049 Efficacy and Safety of Crinone Versus Combination Medication (ACCESS) Status TERMINATED Phase PHASE4
NCT03850444 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study Status COMPLETED Phase PHASE3